Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 778 across all filing types
Latest filing 2015-03-11 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
MAUNA KEA TECHNOLOGIES announces acceleration of installations and use of Cellvizio endomicroscopy platform in Japan
Regulatory Filings Classification · 95% confidence The document is a press release dated March 11, 2015, announcing the acceleration of installations and use of the Cellvizio platform in Japan, highlighting regulatory approval (MHLW), live demonstrations, and physician endorsements. This type of announcement, focusing on business developments, regulatory milestones, and market adoption rather than comprehensive financial results (like a 10-K or IR) or specific insider trading/dividend actions, typically falls under general corporate news or investor relations updates. Since it is not a formal regulatory filing like a 10-K, a specific financial report (IR, AR), or a management/board change (MANG), it best fits the general category for corporate announcements that are not otherwise specified. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release detailing business progress and market adoption, although it is not a formal regulatory submission itself. However, if we strictly interpret the definitions, this is an announcement of business progress, which often accompanies or precedes formal filings. Since there is no specific category for 'Press Release' or 'Business Update', RNS serves as the best general regulatory/announcement category.
2015-03-11 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article L233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and total voting rights as of a specific date (February 27, 2015). This content directly relates to the official disclosure of voting rights and share capital structure, which aligns best with the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), as it is a formal, periodic disclosure of voting power, even if it's not the final result of a specific vote, but rather the underlying structure for voting.
2015-03-04 French
MAUNA KEA TECHNOLGIES, DEUX NOUVELLES PUBLICATIONS PAR UNE ÉQUIPE CHINOISE DE RÉFÉRENCE PRÉSENTENT LES RÉSULTATS POSITIFS DE DEUX ESSAIS CLINIQUES DE GRANDE ENVERGURE
Regulatory Filings Classification · 90% confidence The document is a press release dated March 3, 2015, from Mauna Kea Technologies announcing positive results from two large-scale clinical trials regarding their Cellvizio product, published in major gastroenterology journals. This type of announcement, detailing clinical study outcomes and their implications for the company's technology adoption and reimbursement prospects, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full annual report (10-K), a formal audit report (AR), a management discussion/analysis (MDA), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification for a press release highlighting significant operational/clinical achievements is Earnings Release (ER), as these often accompany or precede formal financial reporting periods, or Regulatory Filings (RNS) if it's purely informational. Given the focus on clinical validation which drives future revenue/market position, ER is a strong candidate, but since it's not explicitly tied to quarterly/periodical financial results (though it discusses clinical validation which supports future results), and it's a general announcement, RNS (Regulatory Filings - the general fallback for announcements) is also plausible. However, press releases announcing major clinical trial successes are frequently categorized under ER if they are material news updates, or sometimes IP if they were presented as an investor presentation, but here it is a publication announcement. Given the context of financial reporting databases, major news releases that aren't explicitly financial results (ER) or management reports (MDA) often fall into the general Regulatory Filings (RNS) category, or if it were a presentation, IP. Since it is a press release announcing published results, RNS is the safest general regulatory announcement category, though ER is often used for material news. I will lean towards RNS as the most general fit for a non-standard regulatory announcement that isn't a specific financial report or management discussion.
2015-03-03 French
MAUNA KEA TECHNOLGIES, TWO NEW PUBLICATIONS FROM LEADING TEAM IN CHINA PRESENT DATA FROM LARGE CLINICAL TRIALS
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 3, 2015, announcing that two new studies highlighting the advantages of the Cellvizio platform in diagnosing gastric and esophageal cancers have been published in peer-reviewed journals (*Gastrointestinal Endoscopy* and *Journal of Clinical Gastroenterology*). This is an announcement about research findings and publications, not the full financial report (10-K, IR), a management change (MANG), or a formal regulatory filing like a dividend notice or insider trade. Since it is an announcement regarding the publication of clinical data and research results, it best fits the category for general regulatory/corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially Investor Presentation (IP) if it were a slide deck, but given the format and content focus on external publication, RNS is the most appropriate general classification for corporate news releases that aren't earnings or capital structure focused. It is not an Earnings Release (ER) or Interim Report (IR). It is a general corporate communication.
2015-03-03 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social' (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code du Commerce, Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a monthly update (as of January 30, 2015) on the total number of shares and voting rights. This type of mandatory periodic disclosure regarding share capital structure and voting rights, especially when presented as a brief, structured update, aligns best with a general regulatory filing or a specific notification about capital structure changes. Since there is no specific code for 'Monthly Voting Rights Update' and it is a direct regulatory disclosure, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not a full financial report (10-K, IR), a dividend notice (DIV), or a director's dealing report (DIRS). Given the context of mandatory regulatory reporting in France, RNS is the most appropriate fallback for this specific type of disclosure.
2015-02-09 French
MAUNA KEA TECHNOLOGIES : RÉSULTATS POSITIFS DE L’ESSAI CLINIQUE PIVOT FOCUS SUR LE RECOURS À L’ENDOMICROSCOPIE CONFOCALE PAR MINISONDE POUR LA DÉTECTION DES CANCERS DES VOIES BILIAIRES
Regulatory Filings Classification · 95% confidence The document is a press release dated January 27, 2015, announcing positive results from a clinical trial ('FOCUS') regarding the use of Cellvizio technology for detecting bile duct cancers. It details study outcomes, quotes investigators, and mentions the publication in a peer-reviewed journal (*Gastrointestinal Endoscopy*). It also includes a forward-looking statement about the next press release date ('Prochain communiqué de presse : résultats 2014 et Chiffre d'affaires 1er trimestre 2015 le 14 avril 2015'). This structure—announcing key operational/clinical news and financial highlights separately—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses heavily on clinical trial results and their immediate impact, it is best classified as an Earnings Release (ER) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on 'Résultats Positifs' and the mention of future financial results, ER is the most appropriate fit among the specific options, as it communicates period-specific performance news, even if clinical rather than purely financial. It is not a full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT). It is a direct announcement of results, not just a notice of publication (RPA).
2015-01-27 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.